News

Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer

12/19/2023

Stephanie Holland

According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...

According to results from the...

12/19/2023

Oncology

Conference Coverage

Front-Line Treatment Options for Ovarian Cancer

12/07/2023

Featuring Bradley Monk, MD

At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.

At the Great Debates & Updates...

12/07/2023

Oncology

News

Ofranergene Obadenovec Plus Paclitaxel Did Not Improve Survival Outcomes Among Patients With Recurrent, Platinum-Resistant Ovarian Cancer

11/13/2023

Stephanie Holland

According to results from the phase 3 OVAL/GOG 3018 study, the addition of ofranergene obadenovec to paclitaxel did not improve progression-free survival (PFS) or overall survival (OS) among patients with recurrent platinum-resistant ovarian...

According to results from the...

11/13/2023

Oncology

Conference Coverage

Addition of Atezolizumab to Chemotherapy and Maintenance Niraparib Did Not Improve PFS or ORR in Late-Relapsing, Recurrent Ovarian Cancer

11/03/2023

Stephanie Holland

According to primary analysis results from the phase 3 ENGOT-Ov41/GEICO 69-O/ANITA study, the addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival (PFS) or objective...

According to primary analysis...

11/03/2023

Oncology

Conference Coverage

Addition of Atezolizumab to Chemotherapy and Maintenance Niraparib Did Not Improve PFS or ORR in Late-Relapsing, Recurrent Ovarian Cancer

11/03/2023

Stephanie Holland

According to primary analysis...

11/03/2023

Oncology

Conference Coverage

Standard of Care Superior to Olaparib With or Without Cediranib Among Patients With Relapsed, Platinum-Sensitive Ovarian Cancer

10/26/2023

Stephanie Holland

According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.

According to data from the phase...

10/26/2023

Oncology

Conference Coverage

Standard of Care Superior to Olaparib With or Without Cediranib Among Patients With Relapsed, Platinum-Sensitive Ovarian Cancer

10/26/2023

Stephanie Holland

According to data from the phase...

10/26/2023

Oncology

Conference Coverage

Maintenance Senaparib Improved PFS Among Patients With Newly Diagnosed, Advanced Ovarian Cancer

10/25/2023

Stephanie Holland

According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...

According to results from the...

10/25/2023

Oncology

Conference Coverage

Maintenance Senaparib Improved PFS Among Patients With Newly Diagnosed, Advanced Ovarian Cancer

10/25/2023

Stephanie Holland

According to results from the...

10/25/2023

Oncology

News

Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Significantly Improved Long-Term Survival Outcomes in Advanced Ovarian Cancer

10/12/2023

Stephanie Holland

According to updated survival results from the phase 3 OVHIPEC-1 trial, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery significantly improved long-term progression-free survival and overall...

According to updated survival...

10/12/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology